Pharma funding and M&A in 2020

a cool $63bn (which was also notable for putting the world’s best-selling drug Humira under the same roof as Botox).

AbbVie/Allergan merger faces renewed public opposition despite divestments

AbbVie. They also highlighted AbbVie’s use of controversial “rebate walls” around its blockbuster immunology products – including Humira and Skyrizi – which the groups say “lead to higher prescription drug prices” and

After FDA refusal, Takeda builds case for subcutaneous Entyvio

AbbVie’s TNF blocker Humira (adalimumab) in a head-to-head trial. ... Analysts at GlobalData have previously suggested that having two formulations of vedolizumab will allow Takeda to compete strongly against well-established ulcerative colitis drugs

20 for 2020 – Five pharma companies to watch

At the moment Humira accounts for nearly two-thirds of AbbVie’s total sales. ... wave of products intended to reduce its reliance on Humira, starting in 2020.

1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]